Why GLP-1 Costs Are a Symptom, Not the Disease

Every benefits conversation I have these days starts the same way: 'What do we do about GLP-1 costs?' It's a fair question. The numbers are real. But I've started pushing back on the framing.

GLP-1 medications are expensive because metabolic disease is expensive. The drugs are a response to a problem that has been building for decades — one that the American healthcare system, and the employer benefit system in particular, has largely failed to address upstream.

The Real Question

When an employer asks 'how do we control GLP-1 costs,' what they're really asking is: how do we manage the financial consequences of a workforce that is, on average, metabolically unwell? That's a harder question. It doesn't have a simple formulary answer.

The employers who will win this decade are the ones who stop treating metabolic disease as a claims problem and start treating it as a workforce health problem. Those are related but not identical frames — and the difference matters enormously for how you design benefits.

What a Better Frame Looks Like

A better frame starts with measurement. You can't manage what you can't see. The Metabolic Health Index was built precisely for this — to give employers a longitudinal view of population-level metabolic health, not just a snapshot of claims costs.

From there, the question becomes: what voluntary, employee-paid structures can we put in place that give employees access to modern care — including GLP-1 pathways where clinically appropriate — without exposing the medical plan to open-ended liability? That's the work. It's harder than adjusting a formulary. But it's the only approach that addresses the symptom and the disease.